Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway

Area of Science:

• Oncology
• Neuroscience
• Stem Cell Biology

Background:

• Glioblastoma multiforme (GBM) is a fatal brain cancer with limited treatment options.
• Brain tumor stem cells (BTSCs) drive tumor growth and resistance to therapy.
• Targeting BTSCs is crucial for effective GBM treatment.

Purpose of the Study:

• To investigate siomycin A as a therapeutic agent against GBM.
• To explore the role of maternal embryonic leucine-zipper kinase (MELK) in BTSC survival.
• To evaluate siomycin A's efficacy in targeting MELK and BTSCs.

Main Methods:

• Used patient-derived GBM sphere cells to enrich for BTSCs.
• Assessed siomycin A's effect on MELK expression and BTSC self-renewal, invasion, and apoptosis.
• Evaluated siomycin A's efficacy in preclinical GBM models (in vitro and in vivo).

Main Results:

• Siomycin A significantly reduced MELK expression in stemlike GBM cells.
• Siomycin A inhibited BTSC self-renewal and invasion, inducing apoptosis.
• Siomycin A treatment reduced tumor growth and prolonged survival in mice with intracranial GBM tumors.
• Siomycin A showed minimal impact on non-stem tumor cells and normal neural stem cells.

Conclusions:

• Siomycin A effectively targets MELK, a key regulator of BTSC survival.
• Siomycin A demonstrates potential as a therapeutic agent for GBM by targeting BTSCs.
• This study presents a novel therapeutic strategy targeting GBM stem cells via a MELK-mediated pathway.